SQ-34017 |
SQ-34017 |
Preclinical |
Bristol-Myers Squibb |
Hypertension |
Details
|
L-363564 |
L-363564 |
Phase Not Specified |
Merck Sharp & Dohme |
Hypertension |
Details
|
SQ-30774 |
SQ-30774 |
Preclinical |
Bristol-Myers Squibb |
Hypertension |
Details
|
Ciprokiren |
RO-449375,RO 449375 |
Preclinical |
Roche |
Hypertension, Heart failure |
Details
|
Terlakiren |
CP-80794,CP 80794,CP80794 |
Phase Ⅱ |
Pfizer |
Hypertension |
Details
|
ES-6864 |
ES-6864 |
Phase Ⅰ |
Daiichi Sankyo |
Hypertension |
Details
|
IONIS-AGT-LRx |
IONISAGTLRx; ISIS-757456; ISISAGTLRx |
Phase Ⅱ |
Ionis Pharmaceuticals |
Hypertension |
Details
|
FK-906 |
FK-906; FR-115906 |
Phase Ⅱ |
Astellas |
Hypertension |
Details
|
SR-43845 |
SR-43845 |
Phase Ⅱ |
Sanofi |
Hypertension |
Details
|
SPP-676 |
SPP-676 |
Phase Ⅰ |
Novartis |
Hypertension |
Details
|
YM-21095 |
YM-21095,YM 21095,YM21095 |
Preclinical |
Astellas |
Hypertension |
Details
|
R-Pep-27 |
R-Pep-27 |
Phase Ⅰ |
National Institutes of Health |
Hypertension |
Details
|
ES-8891 |
ES-8891; RS-8891 |
Phase Ⅰ |
Daiichi Sankyo |
Hypertension |
Details
|
Ro-AAA |
Ro-AAA |
Phase Not Specified |
Roche |
Hypertension |
Details
|
A-74273 |
A-74273 |
Phase Ⅰ |
Abbott |
Hypertension |
Details
|
DSP-9599 |
DSP-9599 |
Phase Ⅰ |
Sumitomo Dainippon |
Hypertension |
Details
|
ICI-219623 |
ICI-219623 |
Preclinical |
AstraZeneca |
Hypertension |
Details
|
Imarikiren hydrochloride |
SCO-272; TAK-272 |
Phase Ⅱ |
Takeda |
Hypertension, Diabetic nephropathy |
Details
|
Remikiren mesilate |
RO-425892; RO-425892/001 |
Phase Ⅱ |
Roche |
Hypertension, Heart failure |
Details
|
SC-32796 |
SC-32796 |
Preclinical |
Pfizer |
Kidney disorders, Hypertension |
Details
|
Zankiren |
A-72517; Abbott-72 517 |
Phase Ⅱ |
Abbott |
Hypertension |
Details
|
H-142 |
H-142 |
Phase Ⅱ |
AstraZeneca |
Hypertension, Heart failure |
Details
|
ACT-178882 |
ACT-178882; MK-1597 |
Phase Ⅰ |
Actelion, Merck Sharp & Dohme |
Hypertension |
Details
|
VTP-27999 |
VTP-27999,VTP27999 |
Phase Ⅰ |
Vitae |
Chronic kidney disease |
Details
|
Ditekiren |
U-71038 |
Phase Ⅱ |
Pfizer |
Hypertension, Heart failure |
Details
|
CGP-38560A |
CGP-38560A |
Phase Ⅰ |
Novartis |
Hypertension |
Details
|
ACT-077825 |
ACT-077825; MK-8141; Act-AAA ,ACT077825,MK8141 |
Phase Ⅱ |
Actelion, Merck Sharp & Dohme |
Hypertension |
Details
|
SPP-1148 |
SPP-1148 |
Phase Ⅰ |
Novartis |
Hypertension |
Details
|
CL-331049 |
CL-331049 |
Preclinical |
Pfizer |
Hypertension |
Details
|
PD-132002 |
PD-132002,PD 132002,PD132002 |
Preclinical |
Pfizer |
Hypertension |
Details
|
A-65317 |
A-65317,A 65317,A65317 |
Preclinical |
Abbott |
Hypertension |
Details
|
ES-305 |
ES-305,ES 305,ES305 |
Preclinical |
Daiichi Sankyo |
Hypertension |
Details
|
Enalkiren |
A-64662; Abbott-64662 |
Phase Ⅱ |
Abbott |
Kidney disorders, Hypertension, Glaucoma |
Details
|
Aliskiren Hemifumarate/Amlodipine Besilate/Hydrochlorothiazide |
|
Withdrawn |
Novartis |
Hypertension |
Details
|
WAY-121604 |
WAY-121604 |
Preclinical |
Pfizer |
Hypertension |
Details
|
L-157119 |
L-157119 |
Phase Not Specified |
Merck Sharp & Dohme |
Hypertension |
Details
|
A-68064 |
A-68064 |
Preclinical |
Abbott |
Hypertension |
Details
|
Aliskiren Hemifumarate/Valsartan |
|
Withdrawn |
Novartis |
Hypertension |
Details
|
SPP-635 |
SPP-635; SPP-630 |
Phase Ⅱ |
Novartis |
Hypertension |
Details
|
SQ-31844 |
SQ-31844 |
Preclinical |
Bristol-Myers Squibb |
Hypertension |
Details
|
SP-20104 (Sarfez Pharmaceuticals) |
SP-20104 |
Phase Ⅱ |
1 A Pharma GmbH |
Focal segmental glomerulosclerosis |
Details
|
A-67449 |
A-67449 |
Phase Not Specified |
Abbott |
Hypertension |
Details
|
GR-70982 |
GR-70982 |
Preclinical |
GlaxoSmithKline |
Hypertension |
Details
|
ES-1005 |
ES-1005 |
Preclinical |
Daiichi Sankyo |
Hypertension |
Details
|